GlaxoSmithKline, the new owner of Rockville’s Human Genome Sciences, cleared a significant regulatory hurdle last week when a Food and Drug Administration advisory panel overwhelmingly recommended that its anthrax treatment be approved.
Under a federal contract, HGS began work on raxibacumab, which it brands ABthrax, shortly after the anthrax attacks in September 2001 that infected 11 people, killing five of them.
{iframe}http://www.gazette.net/article/20121109/NEWS/711099582/-1/anthrax-treatment-developed-by-hgs-headed-for-approval&template=gazette{/iframe}